Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437112 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT00437112 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 142 participants.
The verdict
NCT00437112, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral medications and have not previously taken insulin. Change in HbA1c levels will be reviewed to determine superiority or inferiority of the AIR Inhaled Insulin regimen.
Interventions
- DRUG Insulin Glargine
- DRUG Human Insulin Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437112
The ClinicalTrials.gov registry entry for NCT00437112 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00437112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437112 about?
NCT00437112 is a clinical study titled "Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes". A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral medications and have not previously taken insulin. Change in HbA1c levels ...
What is the current status of trial NCT00437112?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2007-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00437112?
The interventions under investigation include: Insulin Glargine (DRUG), Human Insulin Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT00437112?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.